Aerie Pharmaceuticals, Inc. (AERI) Names Craig R. Skenes As Vice President, Business Development - 6/17

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Craig R. Skenes has been named to the newly established position of Vice President, Business Development at Aerie, reporting directly to Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer. Mr. Skenes has more than two decades of experience in the healthcare industry, having held senior business development leadership positions within ophthalmology and biopharma firms.

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.